
Ascendis Pharma A/S ASND
€ 192.00
-1.5%
Geschäftsbericht 2025
hinzugefügt 18.04.2026
Ascendis Pharma A/S Zahlungsmittel 2011-2026 | ASND
Zahlungsmittel Jährlich Ascendis Pharma A/S
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 616 M | 560 M | 392 M | 445 M | 446 M | 585 M | 598 M | 278 M | 195 M | 180 M | 120 M | - | - | - | - |
Alle Zahlen in EUR-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 616 M | 120 M | 401 M |
Zahlungsmittel Vierteljährlich Ascendis Pharma A/S
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 756 M | 446 M | 693 M | 385 M | 495 M | 585 M | 763 M | 241 M | 534 M | 598 M | 659 M | 690 M | 697 M | 278 M | 310 M | 353 M | 348 M | 195 M | 206 M | 127 M | 158 M | 180 M | - | - | - | 120 M | - | - | - | 50.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in EUR-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 763 M | 50.2 M | 411 M |
Zahlungsmittel anderer Aktien in der Pharmaeinzelhändler
| Name | Zahlungsmittel | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M | ||
|
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K | ||
|
BioNTech SE
BNTX
|
7.68 B | $ 95.5 | -3.88 % | $ 27.2 B | ||
|
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M | ||
|
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | ||
|
Midatech Pharma plc
MTP
|
8.53 M | - | -18.52 % | $ 27.3 M | ||
|
AlloVir
ALVR
|
98.1 M | - | 4.14 % | $ 49.1 M | ||
|
Cerus Corporation
CERS
|
20 M | $ 2.59 | -4.78 % | $ 494 M | ||
|
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B | ||
|
Athira Pharma
ATHA
|
69.3 M | - | - | $ 269 M | ||
|
Cardiff Oncology
CRDF
|
17.5 M | $ 1.61 | -2.42 % | $ 108 M | ||
|
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | ||
|
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
5.71 B | - | - | $ 96.9 B | ||
|
Atreca
BCEL
|
30.8 M | - | -11.76 % | $ 5.79 M | ||
|
Berkeley Lights
BLI
|
86.5 M | - | -7.31 % | $ 87 M | ||
|
Cue Biopharma
CUE
|
27.1 M | $ 34.94 | 17.05 % | $ 3.31 B | ||
|
Calithera Biosciences
CALA
|
59.5 M | - | -10.95 % | $ 876 K | ||
|
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | ||
|
CymaBay Therapeutics
CBAY
|
207 M | - | - | $ 3.45 B | ||
|
ChemoCentryx
CCXI
|
50 M | - | - | $ 3.74 B | ||
|
Editas Medicine
EDIT
|
147 M | $ 3.04 | 1.33 % | $ 270 M | ||
|
Caladrius Biosciences
CLBS
|
16.2 M | - | -16.75 % | $ 25.8 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
50.7 M | - | - | $ 231 M | ||
|
Exelixis
EXEL
|
482 M | $ 44.42 | 0.57 % | $ 12.1 B | ||
|
Aeterna Zentaris
AEZS
|
7.31 M | - | 5.93 % | $ 314 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
320 M | $ 22.35 | 0.72 % | $ 3.7 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
29 K | - | -2.5 % | $ 5.88 M | ||
|
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
83.5 M | - | - | $ 2.18 B | ||
|
AIkido Pharma
AIKI
|
34 M | - | 1.93 % | $ 17.4 M | ||
|
Dynavax Technologies Corporation
DVAX
|
95.9 M | - | - | $ 2.02 B | ||
|
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
66.4 M | - | - | $ 28.6 M | ||
|
Galapagos NV
GLPG
|
87.9 M | $ 28.39 | -0.13 % | $ 2.69 B | ||
|
Grifols, S.A.
GRFS
|
980 M | $ 8.27 | 0.49 % | $ 6.83 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
8.27 M | $ 3.5 | 5.42 % | $ 5.76 M | ||
|
Eiger BioPharmaceuticals
EIGR
|
25.4 M | - | -9.21 % | $ 2.55 M | ||
|
Eloxx Pharmaceuticals
ELOX
|
19.2 M | - | -5.68 % | $ 8.28 M | ||
|
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | ||
|
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | ||
|
ImmuCell Corporation
ICCC
|
3.81 M | $ 8.87 | 1.66 % | $ 80.1 M | ||
|
InflaRx N.V.
IFRX
|
16 M | $ 1.97 | -7.51 % | $ 152 M | ||
|
Applied Therapeutics
APLT
|
49.9 M | - | - | $ 8.42 M | ||
|
Aptose Biosciences
APTO
|
935 K | - | -45.71 % | $ 1.2 M |